|
|
||||||||
Ann Thorac Surg 1995;60:1694-1697
© 1995 The Society of Thoracic Surgeons
Department of Cardiovascular Surgery and Blood Transfusion Service, Kyushu University Hospital, Kyushu University, Fukuoka, Japan
Accepted for publication July 17, 1995.
| Abstract |
|---|
|
|
|---|
Methods. Since 1986, we have instituted a blood conservation program including preoperative autologous blood donations in children. Eighty children as young as 3 years old (mean ± SD, 8.6 ± 3.9 years) and weighing as little as 12.3 kg (29.2 ± 14.5 kg) were enrolled in the program, and 735 ± 388 mL of blood was donated during an average of 3.1 ± 1.5 phlebotomies before the operations.
Results. Two episodes of mild vasovagal reaction were observed in 2 patients as a complication of the phlebotomy. Seventy-six percent of the collected blood was stored by cryopreservation; the remaining 24% was preserved by liquid storage. Seventy-eight of these patients (97.5%) underwent operations using cardiopulmonary bypass. Seventy-five patients (94%) were operated on successfully without the need for a homologous blood transfusion. As for the other 5 patients, 2 received only platelet concentrate.
Conclusion. Preoperative autologous blood donation is a safe and effective method to avoid homologous blood transfusion in pediatric cardiac operations.
| Introduction |
|---|
|
|
|---|
In 1986, we instituted a preoperative autologous blood donation program for cardiovascular surgery, and 665 patients were enrolled in this program until the end of 1994. Among these patients, 80 children (age range, 3 to 15 years) were included. In this article, we introduce our program and its results regarding preoperative autologous blood donation in pediatric cardiac surgery.
| Material and Methods |
|---|
|
|
|---|
Operative Methods
The operative procedures were done for the following conditions: atrial septal defect with or without partial anomalous pulmonary venous drainage (n = 37); ventricular septal defect (18); endocardial cushion defect (3); complex anomaly (7); coronary artery bypass grafting (1); coarctation of the aorta (2); aortic, mitral, and pulmonary valve annuloplasty (3, 2, 1); and aortic, mitral, and tricuspid valve replacement (3, 2, 1, the last with cryosurgery). The two patients operated on through a left thoracotomy for coarctation of the aorta did not have cardiopulmonary bypass; the rest of the patients were operated on using cardiopulmonary bypass. The bypass circuit with a membrane oxygenator was primed with a crystalloid solution (800 mL for body weight less than 30 kg, 1,100 mL for 30 to 40 kg, and 1,600 mL for more than 40 kg), and cardiopulmonary bypass was initiated after systemic administration of 300 U/kg of heparin. The adequacy of anticoagulation therapy was monitored by measurement of the activated clotting time. Additional heparin was given if the activated clotting time was less than 400 seconds. Myocardial protection was performed with an intermittent infusion of crystalloid cardioplegic solution combined with topical cooling with ice slush. An ultrafilter was inserted in parallel with the bypass circuit for hemoconcentration. Protamine sulfate was administered after termination of cardiopulmonary bypass until the activated clotting time normalized. Tranexamic acid, 50 mg/kg, was also given before bypass, 90 minutes after the initiation of bypass, and at termination of bypass to prevent fibrinolysis [6]. The blood lost intraoperatively and blood remaining in the bypass circuit was collected, washed, and reinfused to the patients using a cell-saving system (Cell-Saver; Haemonetics Corporation, Braintree, MA). We did not start the transfusion of predeposited autologous blood until neutralization of heparin with protamine, unless the hematocrit value during bypass became less than 15%.
All values are expressed as mean ± standard deviation. The patients were divided into three subgroups according to age (age less than 5, 6 to 10, and more than 11 years old) for further analysis.
| Results |
|---|
|
|
|---|
At each phlebotomy procedure, an average of 255 ± 96 mL of blood was collected (176 ± 40 mL in patients less than age 5, 217 ± 46 mL for those between 6 and 10, and 356 ± 80 mL in those older than 11). The total stored volume was 735 ± 388 mL for all patients (621 ± 233 mL for those younger than 5, 644 ± 284 mL for those between 6 and 10, and 920 ± 496 mL for those older than 11). Scheduled donations were deferred seven times in 6 patients because of inadequate venous access and once because of anemia. A mild vasovagal reaction was observed two times in 2 patients. The total length of the preoperative donation period was 48 ± 38 days (range, 7 to 140 days), and all patients completed the donation program.
Seventy-six percent of the collected blood was stored by cryopreservation. Cryopreservation was applied more frequently than liquid storage in the younger patients (90% in those less than 5, 83% in those between 6 and 10, and 53% in those older than 11).
The changes in the hemoglobin level are shown in Figure 1
. The hemoglobin level was quite stable during the donation period. At the time of consultation (sampling time 1), the level was 13.1 ± 1.7 g/dL (range, 8.9 to 19.7 g/dL). The lowest hemoglobin concentration during the donation period was 12.3 ± 1.5 g/dL (range, 9.5 to 18.6 g/dL; sampling time 2). The hemoglobin level before operation was 12.8 ± 1.3 g/dL (range, 10.2 to 17.6 g/dL; sampling time 3).
|
Seventy-five of 80 patients (94%) were free from homologous blood transfusion during their hospital stay. There was no need for a homologous blood transfusion in 100% of those under the age of 5, in 90% of those between 6 and 10, and in 93% of those older than 11. The indications for a homologous blood transfusion were anemia associated with low cardiac output in 3 patients and thrombocytopenia in 2 patients. The latter received only platelet concentrate as a homologous blood transfusion.
| Comment |
|---|
|
|
|---|
Complications from allogenic blood transfusion are still unavoidable and can sometimes be fatal, although there has been a tremendous improvement in the detection of transfusion-mediated diseases. In the Fukuoka area, the rate of blood donors seropositive for anti-human T-lymphotropic virus type 1 is high (3.5%), and the seroconversion rate was still not zero despite the transfusion of screened blood [9]. Virus-mediated diseases such as liver cirrhosis (hepatitis virus C) and T-cell leukemia (human T-lymphotropic virus type 1) often present symptoms long after transfusion. The expression of irregular antibodies induced by allogenic blood transfusion might also be a problem at the time of pregnancy and delivery in women. Thus, children tend to benefit more than adults from the prevention of allogenic blood transfusion.
Preoperative autologous blood donation is one of the most effective methods to avoid homologous blood transfusion. It has become popular primarily for elective operations in adults, but recently its indications have been extended to include high-risk patients such as those undergoing cardiac operations [1020]. However, to our knowledge, there have been few reports on the safety and efficacy of preoperative autologous blood donation in children, especially in pediatric cardiac surgery. In Silvergleid's study [14], children as young as 8 years old and weighing as little as 27 kg predonated blood for elective orthopedic or plastic surgery operations. In our study, children as young as 3 years old and weighing as little as 12.3 kg were enrolled in the program before elective cardiac operations, including complex cases such as Fontan's procedure, Rastelli's procedure, and various types of valvular operations.
Generally in pediatric cardiac operations, homologous blood transfusion becomes necessary because primary solution of the bypass circuit and cardioplegic solution cause an overhemodilution of the blood, especially in small patients. Kawamura and associates [21] reported that the safe limit of hemodilution is 50% in ventricular septal defect and 40% in tetralogy of Fallot. The efficacy of blood conservation methods such as ultrafiltration, a cell-saving system, and pharmacologic tools is also quite limited to overcome overhemodilution during cardiopulmonary bypass. Autologous red blood cells are helpful to manage overhemodilution during bypass and to correct anemia after bypass. Autologous fresh frozen plasma is also useful to correct coagulopathy after cardiopulmonary bypass, especially in small patients in whom many coagulating factors are lost by the concentration and washing process of the remaining volume of bypass circuit with a cell-saving system. Although our data are retrospective and nonrandomized, 84% of the patients who underwent cardiac operations concurrently between the ages of 3 and 15 years and who did not predonate required homologous blood transfusion, whereas only 6% of the donating patients received transfusions in our hospital.
One of the most difficult problems in autologous blood donation in children is how best to collect and store the blood. We tried to alleviate the patients' fear by applying local anesthetic agents to the puncture site. The Matsuzaki set (BB-2 IP-2; Kawasumi Chemical Inc, Tokyo, Japan) allows a single puncture for both drainage and infusion use, so the patients receive only a single puncture for every phlebotomy. In the case of inadequate venous access, donation should be postponed to another day to let the patients recover psychologically. When the operative indications are sure, an initial donation at the time of catheterization is recommended. For the storage of blood in children, cryopreservation is useful to prevent phlebotomy-induced anemia. Although mannitol-adenine-phosphate solution can extend the liquid preservation period to up to 6 weeks, cryopreservation is required for most patients under 10 years of age. For example, when the patient is 4 years old, a 3- to 4-week interval is necessary for each donation after the removal of a maximum of 200 mL of blood, and so the collected blood should be stored by cryopreservation. Alternatives such as the leapfrog method and switchback method are not recommended because they are cumbersome to perform on children. Supplementation with oral iron and an appropriate interval between donations helped to keep the hemoglobin level stable during the preoperative donation period.
It is difficult to determine the minimum requirement of autologous blood to avoid homologous blood transfusion. There are many factors, such as body weight, hemoglobin level, and operative procedures, that affect the need for blood transfusion. The indications for blood transfusion also play an important role. The oxygen-carrying capacity and cardiac output are important determinants for red blood cell transfusion. A hematocrit value of approximately 20% is acceptable during cardiopulmonary bypass [22]. Although we usually allow a hematocrit value of 20% in adults, a hematocrit value of 15% is also acceptable in simple cases such as atrial septal defect and ventricular septal defect when venous oxygen saturation, as monitored by Oxy-Sat (Baxter Healthcare Corporation, Irvine, CA), is satisfactory. In this series, only 3 patients (3.8%) required a red blood cell component transfusion because of anemia combined with a severely low cardiac output. Based on this high success rate, we consider that the stored red cell volume in our series was satisfactory.
The indication for autologous blood transfusion is quite different from that for homologous blood transfusion. At the initial stage of this program, we tried to store as much autologous blood as possible and transfused all donated blood to the patients, which caused polycythemia in 2 patients. Afterward, we changed our policy and determined that the predonated autologous blood should not be transfused to the patients when the hemoglobin level is greater than 15 g/dL. Thanks to our experience with preoperative autologous blood donation, including nearly 600 adults, we can now accurately predict the blood requirement. As a result, in principle, all donated blood is transfused back to the patients.
Recent advances in pediatric cardiac surgery have helped to lower the age for correction of cardiac anomalies. In our institute, half of the children who undergo cardiac operations are less than 3 years old. This means that less than half of the children qualify for preoperative autologous blood donation. In addition, most of our cases were simple congenital malformations because such malformations tend to have good operative indications in the age range studied, although complex anomalies were also included in our series. Further efforts to lower the indicated age for blood donation are thus required to enable smaller children to benefit from our blood-saving program.
In this study, 2 patients who underwent Rastelli's procedure required only platelet concentrate for the homologous blood transfusion. To improve our program, we are now considering the introduction of preoperative donation of autologous platelets [23].
In conclusion, preoperative autologous blood donation in pediatric cardiac operations is considered to be a safe and effective method to avoid homologous blood transfusion and may also prevent transfusion-transmitted diseases.
| Addendum |
|---|
|
|
|---|
| Acknowledgments |
|---|
|
|
|---|
| Footnotes |
|---|
|
|
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
N. Hibino, M. Nagashima, H. Sato, T. Hori, H. Ishitoya, and T. Tomino Preoperative Autologous Blood Donation for Cardiac Surgery in Children Asian Cardiovasc Thorac Ann, February 1, 2008; 16(1): 21 - 24. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Sonzogni, G. Crupi, R. Poma, F. Annechino, F. Ferri, P. Filisetti, and P. Bellavita Erythropoietin therapy and preoperative autologous blood donation in children undergoing open heart surgery Br. J. Anaesth., September 1, 2001; 87(3): 429 - 434. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Masuda, Y. Moriyama, K. Hisatomi, R. Toda, S. Shimokawa, Y. Iguro, S.-i. Watanabe, H. Matsumoto, and A. Taira Preoperative autologous donation of blood for a simple cardiac anomaly: Analysis of children weighing under twenty kilograms J. Thorac. Cardiovasc. Surg., October 1, 2000; 120(4): 783 - 788. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |